+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Protection of Midazolam Against Immune Mediated Liver Injury Induced by Lipopolysaccharide and Galactosamine in Mice



The Protection of Midazolam Against Immune Mediated Liver Injury Induced by Lipopolysaccharide and Galactosamine in Mice



Frontiers in Pharmacology 9: 1528



Objectives: Liver macrophages agitated by Lipopolysaccharide (LPS) can enhance immuno-inflammatory responses in the liver which mediate liver injury and result in dysfunction. Midazolam has been reported to have inhibitory effects on activated immunity and escalated inflammation, however, what the effects of midazolam on the liver injury caused by excessive immuno-inflammatory response in sepsis, and what influence it will exert on inflamed liver macrophages need to be elucidated. Methods: In the present study, LPS and galactosamine-induced acute liver injury mice were used to observe the effect of midazolam in vivo. LPS-stimulated bone marrow cells were used to evaluate the influence of midazolam on monocytes in vitro. Results: Midazolam prevented liver tissue injury and decreased serum alanine transaminase (ALT) level in LPS plus galactosamine treated mice. Mechanistically, midazolam suppressed tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) produced by LPS stimulated liver macrophages in vivo and bone marrow monocytes in vitro, and reduced the expression of major histocompatibility complex class II (MHC II), cluster of differentiation 40 and 86 (CD40 and CD86) on the cell surface. These results could be reversed by PK-11195, a peripheral benzodiazepine receptor (PBR) blocker. Conclusion: Midazolam can prevent liver from LPS-induced immune mediated liver injury by inhibiting inflammation and immune activation in liver macrophages.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066113854

Download citation: RISBibTeXText

PMID: 30670973

DOI: 10.3389/fphar.2018.01528


Related references

Prostacyclin mimetics afford protection against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. Toxicology and Applied Pharmacology 334: 55-65, 2017

Nobiletin attenuates lipopolysaccharide/D‑galactosamine‑induced liver injury in mice by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF‑κB‑mediated cytokine production. Molecular Medicine Reports 14(6): 5595-5600, 2016

In vitro inhibition of lipopolysaccharide and mycobacterium bovis bacillus Calmette Guérin-induced inflammatory cytokines and in vivo protection from D-galactosamine/LPS -mediated liver injury by the medicinal plant Sclerocarya birrea. International Journal of Immunopathology and Pharmacology 23(1): 61-72, 2010

Recql5 protects against lipopolysaccharide/D-galactosamine-induced liver injury in mice. World Journal of Gastroenterology 21(36): 10375-10384, 2015

Oxyresveratrol prevents lipopolysaccharide/ d -galactosamine-induced acute liver injury in mice. International Immunopharmacology 56: 105-112, 2018

Dopamine alleviated acute liver injury induced by lipopolysaccharide/d-galactosamine in mice. International Immunopharmacology 61: 249-255, 2018

Protective effect of linalool against lipopolysaccharide/D-galactosamine-induced liver injury in mice. International Immunopharmacology 23(2): 523-529, 2014

Esculin prevents Lipopolysaccharide/D-Galactosamine-induced acute liver injury in mice. Microbial Pathogenesis 125: 418-422, 2018

Oxyresveratrol prevents lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. International Immunopharmacology 56: 105-112, 2018

Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World Journal of Gastroenterology 12(21): 3352-3358, 2006

Dexmedetomidine alleviated lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. International Immunopharmacology 72: 367-373, 2019

Reduction in activating transcription factor 4 promotes carbon tetrachloride and lipopolysaccharide/D‑galactosamine‑mediated liver injury in mice. Molecular Medicine Reports 18(2): 1718-1725, 2018

Protective Effects of Costunolide Against D-Galactosamine and Lipopolysaccharide-Induced Acute Liver Injury in Mice. Frontiers in Pharmacology 9: 1469, 2018

Protective effect of soyasaponins on acute liver injury induced by D-galactosamine and lipopolysaccharide in mice. Zhongguo Zhong Yao Za Zhi 38(13): 2187-2190, 2013

Protective effects of garcinol in mice with lipopolysaccharide/D-galactosamine-induced apoptotic liver injury. International Immunopharmacology 19(2): 373-380, 2014